DCIS.

Lisa Scheidegger1, Heike Frauchiger-Heuer2, Esther Birindelli2

  • 1Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland; Department of Anesthesiology and Perioperative Medicine, University Hospital Zurich, Zurich, Switzerland.

Human pathology
|August 9, 2025
PubMed
概括

管道癌 in situ (DCIS) 的微侵袭并没有显著改变整体复发率. 然而,具有特定高风险特征的微侵袭性DCIS需要进一步研究以制定量身定制的治疗策略.